ProQR Therapeutics N.V. - Ordinary Shares (PRQR) News
Filter PRQR News Items
PRQR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRQR News Highlights
- PRQR's 30 day story count now stands at 2.
- Over the past 20 days, the trend for PRQR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- EARN, EU and RNA are the most mentioned tickers in articles about PRQR.
Latest PRQR News From Around the Web
Below are the latest news stories about PROQR THERAPEUTICS NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
Is ProQR (PRQR) Stock a Solid Choice Right Now?ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic AssetsDivestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU Transaction supports ProQR’s strategic focus on its proprietary Axiomer® RNA editing technology platform and continued advancement of pipeline LEIDEN, Netherlands & CAMB |
ProQR Announces Third Quarter 2023 Operating and Financial ResultsContinued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United States and successful defense against opposition to its IP in Japan€120.6 M cash and cash equivalents as of September 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE |
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA EditingLEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the United States and that it has successfully defended against an opposition to its IP in Japan. “The new patent that the USPTO granted to ProQR further expands the protectio |
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines ConferenceLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Daniel A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City. The panel is scheduled for October 2, 2023 at 9:30 am – 10:15 a |
ProQR Therapeutics Provides Update on Ophthalmic AssetsLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a number of key ophthalmology |
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ConferenceLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference. A webcast of the Company’s presentation will be available from the “Investors & Media” section of ProQR’s website un |
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutionsKey Insights The considerable ownership by retail investors in ProQR Therapeutics indicates that they collectively have... |
ProQR Announces Second Quarter 2023 Operating and Financial ResultsDivestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing |
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic AssetsAgreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform and continued advancement of pipeline programs, AX-0810 and AX-1412, focused on genetic diseases originating in the liver LEIDEN, Netherlands, CAMBRIDGE, Mass., and CLERMONT FERRAND, France, Aug. 01, 2 |